Follow-up rates were similar in the treated and untreated groups, with slightly more adverse events demonstrated in the Paxlovid vs control group. Researchers conducted a retrospective electronic ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. To assess the risk of GBS with these vaccines, the FDA conducted a postmarketing ...